Unknown

Dataset Information

0

Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects.


ABSTRACT: Disruption of the cell cycle is among the most effective approach to increase tumour cells' radio-sensitivity. However, the presence of dose-limiting side effects hampers the clinical use of tyrosine kinase inhibitors targeting the cell cycle. Towards addressing this challenge, we identified a bosutinib nanoformulation within high density lipoprotein nanoparticles (HDL NPs) as a promising radiosensitiser. Bosutinib is a kinase inhibitor clinically approved for the treatment of chronic myeloid leukemia that possesses radiosensitising properties through cell cycle checkpoint inhibition. We found that a remarkably high bosutinib loading (> 10%) within HDL NPs could be reliably achieved under optimal preparation conditions. The radiosensitisation activity of the bosutinib-HDL nanoformulation was first assessed in vitro in UM-SCC-1 head and neck squamous cell carcinoma (HNSCC) cells, which confirmed efficient disruption of the radiation induced G2/M cell cycle arrest. Interestingly, the bosutinib nanoformulation out-performed free bosutinib, likely because of the specific affinity of HDL NPs with tumour cells. The combination of bosutinib-HDL NPs and radiotherapy significantly controlled tumour growth in an immunocompetent murine HNSCC model. The bosutinib-HDL nanoformulation also enhanced the radiation induced immune response through the polarisation of tumour associated macrophages towards proinflammatory phenotypes.

SUBMITTER: Dehghankelishadi P 

PROVIDER: S-EPMC10028769 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects.

Dehghankelishadi Pouya P   Badiee Parisa P   Maritz Michelle F MF   Dmochowska Nicole N   Thierry Benjamin B  

Journal of nanobiotechnology 20230321 1


Disruption of the cell cycle is among the most effective approach to increase tumour cells' radio-sensitivity. However, the presence of dose-limiting side effects hampers the clinical use of tyrosine kinase inhibitors targeting the cell cycle. Towards addressing this challenge, we identified a bosutinib nanoformulation within high density lipoprotein nanoparticles (HDL NPs) as a promising radiosensitiser. Bosutinib is a kinase inhibitor clinically approved for the treatment of chronic myeloid le  ...[more]

Similar Datasets

| S-EPMC9710765 | biostudies-literature
2020-08-31 | GSE156800 | GEO
| S-EPMC4617360 | biostudies-literature
| S-EPMC3807967 | biostudies-literature
| S-EPMC9059646 | biostudies-literature
| S-EPMC10053475 | biostudies-literature
| S-EPMC4516847 | biostudies-literature
| S-EPMC7043958 | biostudies-literature
| S-EPMC11191326 | biostudies-literature
| S-EPMC2843502 | biostudies-literature